Therapeutic options for assisted reproduction in patients with impaired ovarian reserve
Authors:
R. Hudeček; I. Prokopová; M. Sviteková; R. Krajčovičová
Authors place of work:
Gynekologicko-porodnická klinika LF MU a FN Brno
Published in the journal:
Prakt Gyn 2010; 14(1): 26-35
Category:
Review Article
Summary
The paper provides a literature review of pathophysiological, epidemiological and etiological factors associated with impaired ovarian function in women. The association between ovarian dysfunction and age, the role of genetics in impaired ovarian function, autoimmune and iatrogenic as well as other potential causes of impaired ovarian reserve are discussed. The authors present own clinical project focussing on the options for assisted reproduction in the group of patients with age‑related impaired ovarian reserve. Aims of the study: Clinical analysis of therapeutic options within the programme of assisted reproduction (AR) in patients above 40 years of age and evaluation of effectiveness of the selected approaches. Materials: The cohort consisted of patients cared for at the Centre for Assisted Reproduction CAR 01 of the Clinic of Gynaecology and Obstetrics, University Hospital in Brno, above 40 years of age who underwent an AR treatment cycle between 1st Jan 2003 and 30th Sep 2004 (total of 118 AR cycles at CAR 01 CGO UH in Brno). The patients within the cohort were stratified according to the approach to infertility treatment. IVF group: Patients who underwent a cycle with ovulation induction and aspiration of own oocytes (38 cycles, 3.7 % of all AR cycles). OD group: patients who utilised the oocyte donation programme (65 cycles, 6.4 % of all AR cycles). ED group: patients who utilised the embryo donation programme (15 cycles, 1.4 % of all AR cycles). Methods: The effectiveness of the specific treatment approach in the respective treatment group of patients was evaluated – the total use of gonadotropic hormones (rFSH), % cycles with oocyte aspiration (OR), the mean number of oocytes obtained (OO), the mean % of fertilized oocytes (Fertilization Rate, FR), % of cycles resulting in embryo transfer (ET), % of cycles with cryopreservation of excess embryos (KRYO) and % of obtained clinical pregnancies on ET (GR/ ET). The optimum therapeutic approach in patients above the age of 40 was defined. Results: IVF group: Total of 38 cycles in patients who underwent ovulation induction, the mean use of 2550IU rec- FSH, aspiration of own oocytes in 89.5 % of patients with an average yield of 6 oocytes per aspiration. At the fertilization rate of 76.2 %, 74.3 % of patients underwent embryotransfer. Good quality excess oocytes were cryopreserved in 15.8 % of cycles. Pregnancy rate in this group was 7.00 %. OD group: Total of 65 cycles in oocyte donation patients. The patients received a mean of 4.5 oocytes per cycle and, at the fertilization rate of 83.1 %, 100.0 % of patients underwent embryotransfer. Good quality excess oocytes were cryopreserved in 1.5 % of cycles. Pregnancy rate in this group was 26.2 %. ED group: Total of 15 cycles in embryo donation patients. 100 % of patients underwent embryotranfer. No embryos were cryopreserved. Pregnancy rate in this group was 13.3 %. Conclusion: The oocyte donation programme represents the most effective approach to infertility treatment in patients with age‑related impaired ovarian reserve (40 years and above). Oocyte donation represents a rational approach that from an ethical perspective represents an exclusive and specific entity. The number of patients with impaired ovarian function within the assisted reproduction programme increases. Demographic and epidemiological data from the Czech Republic suggest that the importance of this issue will increase with time. Considering the variety of etiological factors that might alter ovarian function, careful differential diagnosis is crucial. The efficacy of therapeutic management might be improved following identification of the underlying cause. Even though treatment success is limited in patients with impaired ovarian function and their management is highly demanding with respect to diagnostics and therapy, the options currently available in assisted reproduction provide this group of women with real chance for fulfilment of their reproductive functions.
Key words:
impaired ovarian reserve – premature ovarian failure – disorders of reproduction – assisted reproduction – oocyte donation
Zdroje
1. Altchek A, Deligdisch L, Kase NG. Diagnosis and management of ovarian disorders. 2nd ed, New York: Academic Press 2003: 169– 179.
2. Antinori S, Versaci C, Gholami G et al. Oocyte donation in menopausal women. Hum Reprod 1993; 8(9): 1487– 1490.
3. Belaisch- Allart J, Devaux A, Ayel J et al. Women of 40 and older in i.v.f. and i.c.s.i.: the FIVNAT data. Gynecol Obstet Fertil 2004; 32(9): 730– 736.
4. Burcin B, Caithamlová E, Kučera T et al. Demografické souvislosti asistované reprodukce v České republice a na Slovensku. Prakt Gyn 2004; 8(5): 11– 12.
5. Cameron IT, O’Shea FC, Rolland JM. Occult ovarian failure: a syndrome of infertility, regular menses, and elevated follicle- stimulating hormone concentrations. J Clin Endocrinol Metab 1988; 67(6): 1190– 1194.
6. Cibula D, Živný J. Syndrom předčasného ovariálního selhání. Čes Gynek 2000; 65(2): 98– 102.
7. Cibula D, Henzl RM, Živný J et al. Základy gynekologické endokrinologie. 1. vyd. Praha: Grada publishing 2002: 239– 274.
8. Cicinelli E, Cignarelli M, Resta L et al. Effects of the repetitive administration of progesterone by nasal spray in postmenopausal women. Fertil Steril 1993; 60(6): 1020– 1024.
9. Fajt T, Vrablík M. Vývoj názorů na vliv hormonální substituční terapie na riziko ischemické choroby srdeční. Prakt Gyn 2002; 6(6): 19– 21.
10. Fajt T. Má perorální kombinovaná kontracepce vliv na riziko osteoporózy? Prakt Gyn 2002; 6(6): 11– 12.
11. Fajt T. Novinky v klimakterické medicíně. Prakt Gyn 2002; 6(4): 18– 21.
12. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update 2005; 11(4): 391– 410.
13. Hudeček R, Ventruba P, Juránková E et al. Terapeutické možnosti asistované reprodukce u perimenopauzálních žen. Prakt Gyn 2004; 8(6): 6– 9.
14. Huser M, Juránková E, Crha I et al. Fertility preservation strategie in women undergoing chemotherapy for haematological malignancy. Eur Clinics Obstet Gynaecol 2006; 2: 77– 81.
15. Huser M, Juránková E, Crha I et al. Kryokonzervace ovariální tkáně – šance na záchranu fertility žen s nádorovým onemocněním. Čes Gynek 2007; 72(1): 68– 73.
16. La Marca A, Marzotti S, Brozzetti A et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab 2009; 94(10): 3816– 3823.
17. Li CZ, Liu B, Wen ZQ et al. The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts: a prospective clinical study of 191 patients. Fertil Steril 2009; 92(4):1428– 1435.
18. Lutjen P, Trounson A, Leeton J et al. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature 1984; 307(5947): 174– 175.
19. Mardesic T, Müller P, Zeťová L et al. Factors affecting the results of in vitro fertilization. Importance of the stimulation protocols combining GnRH analogs and HMG in women with unsuccessful stimulation with combinations of clomiphene citrate- HMG. Česká Gynekol 1995; 60(2): 74– 78.
20. Mardesic T, Hulvert J, Miková M et al. Hormone replacement for pregnancy in functionally agonadal women after transfer of thawed embryos in the in vitro fertilization program – problems of placental incompetence. Česká Gynekol 1998; 63(5): 402– 405.
21. Massin N, Gougeon A, Meduri G. Significance of ovarian histology in the management of patients presenting a premature ovarian failure. Hum Reprod 2004; 19(11): 2555– 2560.
22. Meskhi A, Seif MW. Premature ovarian failure. Curr Opin Obstet Gynecol 2006; 18(4): 418– 426.
23. Navot D, Bergh PA, Williams MA et al. Poor oocyte quality rather than implantation failure as a cause of age‑related decline in female fertility. Lancet 1991; 337(8754): 1375– 1377.
24. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil Steril 1990; 53(2): 288– 294.
25. Santoro N. Mechanisms of premature ovarian failure. Ann Endocrinol (Paris) 2003; 64(2): 87– 92.
26. Sauer MV, Paulson RJ, Lobo RA. A preliminary report on oocyte donation extending reproductive potential to women over 40. N Engl J Med 1990; 323(17): 1157– 1160.
27. Sauer MV, Paulson RJ, Lobo RA. Pregnancy after age 50: application of oocyte donation to women after natural menopause. Lancet 1993; 341(8841): 321– 323.
28. Serhal PF, Craft IL. Oocyte donation in 61 patients. Lancet 1989; 1(8648): 1185– 1187.
29. Shahine LK, Lathi RB, Baker VL. Oocyte retrieval versus conversion to intrauterine insemination in patients with poor response to gonadotropin therapy. Fertil Steril 2009; 92(4): 1315– 1317.
30. Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med 1982; 306(7): 409– 412.
31. Schimberni M, Morgia F, Colabianchi J et al. Natural- cycle in vitro fertilization in poor responder patients: a survey of 500 consecutive cycles. Fertil Steril 2009; 92(4): 1297– 1301.
32. Streda R, Mardesic T, Sobotka V et al. Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected patients – hormonal and cycle characteristics. Česká Gynekol 2009; 74(2): 75– 80.
33. Ventruba P, Višňová H, Hudeček R. Kam směřuje vývoj asistované reprodukce v České republice? Národní registr ART 1993– 1996. Prakt Gyn 1997; 1(5): 20.
34. Ventruba P, Mardesic T, Pilka L et al. Registr asistované reprodukce: výsledky a analýza komplikací. Česká Gynekol 1998; 63: 39– 41.
35. Ventruba P, Višňová H, Hudeček R et al. 10 let národního registu asistované reprodukce v ČR. Asistovaná reprodukce 1997; 7(1): 6– 7.
36. Vital Reyes VS, Téllez Velasco S, Hinojosa Cruz JC. Serum levels of IL‑1beta, IL‑6 and TNF‑alpha in infertile patients with ovarian dysfunction. Gynecol Obstet Mex 2005; 73(11): 604– 610.
37. Vital Reyes VS, Tellez Velasco S, Hinojosa Cruz JC. Ovarian apoptosis. Gynecol Obstet Mex 2001; 69: 101– 107.
38. Vital Reyes VS, Tellez Velasco S, Hinojosa Cruz JC. Ovarian biopsy in infertile patiens with ovarian dysfunction. Int J Gynecol Pathol 2006; 25(1): 90– 94.
39. Wang B, Li L, Ni F et al. Mutational analysis of SAL- Like 4 (SALL4) in Han Chinese women with premature ovarian failure. Mol Hum Reprod 2009; 15(9): 557– 562.
40. Wu R, Van der Hoek KH, Ryan NK. Macrophage contributions to ovarian function. Hum Reprod Update 2004; 10(2): 119– 133.
41. Yan G, Schoenfeld D, Penney C. Identification of premature ovarian failure patients with underlying autoimmunity. J Womens Health Gend Based Med 2000; 9(3): 275– 287.
42. Zintzaras E. Inhibin alpha gene and susceptibility to premature ovarian failure: a data synthesis. Molr Hum Reprod2009; 15(9): 551– 555.
43. Žáková J, Vetruba P, Crha I et al. Možnost využití darovaných gamet nebo embryí při léčbě neplodnosti. Prakt Gyn 2006; 9(3): 105– 107.
44. Visser JA, de Jong FH, Laven JS et al. Anti‑Müllerian hormone: a new marker for ovarian function. Reproduction 2006, 131(1): 1– 9.
45. Fanchin R, Schonäuer LM, Righini C et al. Serum anti‑Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reproduction 2003; 18(2), 323– 327.
46. Kwee J, Elting ME, Schats R et al. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007; 5: 9.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Practical Gynecology
2010 Číslo 1
Najčítanejšie v tomto čísle
- Margin status of conizations with histological finding carcinoma in situ
- ICTP marker and breast cancer with bone metastases – our experience
- Intrahepatic cholestasis of pregnancy – selected perinatal outcomes.
- Therapeutic options for assisted reproduction in patients with impaired ovarian reserve